Symbols / TRVI Stock $14.80 +1.23% Trevi Therapeutics, Inc.
TRVI (Stock) Chart
About
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Stock Fundamentals
Scroll to Statements| Market Cap | 2.10B | Enterprise Value | 1.71B | Income | -42.76M | Sales | — | Book/sh | 1.43 | Cash/sh | 1.47 |
| Dividend Yield | — | Payout | 0.00% | Employees | 34 | IPO | — | P/E | — | Forward P/E | -26.19 |
| PEG | — | P/S | — | P/B | 10.36 | P/C | — | EV/EBITDA | -34.82 | EV/Sales | — |
| Quick Ratio | 19.41 | Current Ratio | 19.66 | Debt/Eq | 0.41 | LT Debt/Eq | — | EPS (ttm) | -0.32 | EPS next Y | -0.56 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-07 | ROA | -20.26% | ROE | -30.23% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 141.74M | Shs Float | 105.98M | Short Float | 13.69% |
| Short Ratio | 11.12 | Short Interest | — | 52W High | 16.12 | 52W Low | 5.38 | Beta | 1.00 | Avg Volume | 1.49M |
| Volume | 1.25M | Target Price | $21.91 | Recom | Strong_buy | Prev Close | $14.62 | Price | $14.80 | Change | 1.23% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-17 | main | D. Boral Capital | Buy → Buy | $19 |
| 2026-03-19 | main | Jones Trading | Buy → Buy | $24 |
| 2026-03-18 | main | Morgan Stanley | Overweight → Overweight | $18 |
| 2026-03-18 | main | D. Boral Capital | Buy → Buy | $19 |
| 2026-03-18 | main | Needham | Buy → Buy | $24 |
| 2026-03-09 | main | D. Boral Capital | Buy → Buy | $19 |
| 2026-03-09 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2026-01-09 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2026-01-08 | main | D. Boral Capital | Buy → Buy | $19 |
| 2025-12-19 | main | Stifel | Buy → Buy | $18 |
| 2025-11-20 | main | Leerink Partners | Outperform → Outperform | $16 |
| 2025-11-14 | main | D. Boral Capital | Buy → Buy | $19 |
| 2025-11-14 | main | Oppenheimer | Outperform → Outperform | $24 |
| 2025-11-14 | main | Morgan Stanley | Overweight → Overweight | $19 |
| 2025-11-14 | main | Clear Street | Buy → Buy | $21 |
| 2025-08-21 | init | Morgan Stanley | — → Overweight | $18 |
| 2025-08-08 | main | Raymond James | Strong Buy → Strong Buy | $27 |
| 2025-08-08 | main | Needham | Buy → Buy | $22 |
| 2025-07-01 | init | Cantor Fitzgerald | — → Overweight | $25 |
| 2025-06-02 | main | D. Boral Capital | Buy → Buy | $21 |
- TRVI stock’s five-day rally pushes it to an all-time high – here’s what’s happening - MSN hu, 23 Apr 2026 00
- Trevi Therapeutics (TRVI) Stock: Is It Holding Support | Q4 2025: Earnings Beat Estimates - Equity Raise - Cổng thông tin điện tử Tỉnh Sơn La hu, 23 Apr 2026 02
- Trevi brings in $173M after underwriters buy all extra shares - Stock Titan Mon, 20 Apr 2026 20
- Trevi Therapeutics (TRVI) Stock: Is It Holding Support | Q4 2025: Earnings Beat Estimates - Revision Upgrade - Xã Vĩnh Công hu, 23 Apr 2026 00
- Did Trevi’s US$173 Million Raise and Share Expansion Just Reshape Trevi Therapeutics' (TRVI) Investment Narrative? - Yahoo Finance Wed, 22 Apr 2026 13
- Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat Wed, 22 Apr 2026 08
- Trevi Therapeutics: Late-Stage Transition Meets Execution Risk (NASDAQ:TRVI) - Seeking Alpha Fri, 17 Apr 2026 18
- What's Going On With Trevi Therapeutics Stock? - Benzinga Fri, 17 Apr 2026 15
- TREVI THERAPEUTICS ($TRVI) Releases Q4 2025 Earnings | TRVI Stock News - Quiver Quantitative ue, 17 Mar 2026 07
- TRVI Forecast, Price Target & Analyst Ratings | TREVI THERAPEUTICS INC (NASDAQ:TRVI) - ChartMill Fri, 17 Apr 2026 07
- Trevi sells 11.6M shares at $13, aiming to raise about $150M - Stock Titan Fri, 17 Apr 2026 07
- Trevi Therapeutics (TRVI) Stock: Slowing Down? (Breakout Watch) 2026-04-18 - Trending Picks - Cổng thông tin điện tử tỉnh Lào Cai Sat, 18 Apr 2026 11
- Trevi Therapeutics (NASDAQ: TRVI) asks holders to OK share, equity plan boosts - Stock Titan ue, 21 Apr 2026 20
- Trevi seeks $150M from investors, with option for $22.5M more - Stock Titan hu, 16 Apr 2026 20
- Trevi Therapeutics (NASDAQ: TRVI) raises $150M in stock sale - Stock Titan Fri, 17 Apr 2026 12
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
49.33
-4.26%
|
51.52
+51.89%
|
33.92
+13.43%
|
29.91
|
| Research And Development |
|
33.48
-14.98%
|
39.38
+66.27%
|
23.68
+19.41%
|
19.83
|
| Selling General And Administration |
|
15.85
+30.48%
|
12.15
+18.62%
|
10.24
+1.66%
|
10.07
|
| General And Administrative Expense |
|
15.85
+30.48%
|
12.15
+18.62%
|
10.24
+1.66%
|
10.07
|
| Other Gand A |
|
15.85
+30.48%
|
12.15
+18.62%
|
10.24
+1.66%
|
10.07
|
| Total Expenses |
|
49.33
-4.26%
|
51.52
+51.89%
|
33.92
+13.43%
|
29.91
|
| Operating Income |
|
-49.33
+4.26%
|
-51.52
-51.89%
|
-33.92
-13.43%
|
-29.91
|
| Total Operating Income As Reported |
|
-49.33
+4.26%
|
-51.52
-51.89%
|
-33.92
-13.43%
|
-29.91
|
| EBITDA |
|
-42.68
+10.69%
|
-47.79
-67.20%
|
-28.58
-2.15%
|
-27.98
|
| Normalized EBITDA |
|
-42.68
+10.69%
|
-47.79
-67.20%
|
-28.58
-2.69%
|
-27.84
|
| Reconciled Depreciation |
|
0.14
-2.04%
|
0.15
+19.51%
|
0.12
+186.05%
|
0.04
|
| EBIT |
|
-42.82
+10.67%
|
-47.94
-66.99%
|
-28.71
-2.43%
|
-28.02
|
| Total Unusual Items |
|
—
|
—
|
—
|
-0.15
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
-0.15
|
| Net Income |
|
-42.76
+10.75%
|
-47.91
-64.84%
|
-29.07
+0.30%
|
-29.15
|
| Pretax Income |
|
-42.82
+10.68%
|
-47.94
-64.76%
|
-29.10
+0.31%
|
-29.19
|
| Net Non Operating Interest Income Expense |
|
6.54
+81.66%
|
3.60
-17.42%
|
4.36
+655.11%
|
0.58
|
| Interest Expense Non Operating |
|
0.00
-100.00%
|
0.00
-98.98%
|
0.39
-66.38%
|
1.16
|
| Net Interest Income |
|
6.54
+81.66%
|
3.60
-17.42%
|
4.36
+655.11%
|
0.58
|
| Interest Expense |
|
0.00
-100.00%
|
0.00
-98.98%
|
0.39
-66.38%
|
1.16
|
| Interest Income Non Operating |
|
6.54
+81.45%
|
3.60
-24.14%
|
4.75
+172.87%
|
1.74
|
| Interest Income |
|
6.54
+81.45%
|
3.60
-24.14%
|
4.75
+172.87%
|
1.74
|
| Other Income Expense |
|
-0.03
-106.67%
|
-0.01
-103.20%
|
0.47
+230.28%
|
0.14
|
| Other Non Operating Income Expenses |
|
-0.03
-106.67%
|
-0.01
-103.20%
|
0.47
+62.28%
|
0.29
|
| Gain On Sale Of Security |
|
—
|
—
|
—
|
-0.15
|
| Tax Provision |
|
-0.06
-113.33%
|
-0.03
+6.25%
|
-0.03
+11.11%
|
-0.04
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
+100.00%
|
-0.00
|
| Net Income Including Noncontrolling Interests |
|
-42.76
+10.75%
|
-47.91
-64.84%
|
-29.07
+0.30%
|
-29.15
|
| Net Income From Continuing Operation Net Minority Interest |
|
-42.76
+10.75%
|
-47.91
-64.84%
|
-29.07
+0.30%
|
-29.15
|
| Net Income From Continuing And Discontinued Operation |
|
-42.76
+10.75%
|
-47.91
-64.84%
|
-29.07
+0.30%
|
-29.15
|
| Net Income Continuous Operations |
|
-42.76
+10.75%
|
-47.91
-64.84%
|
-29.07
+0.30%
|
-29.15
|
| Normalized Income |
|
-42.76
+10.75%
|
-47.91
-64.84%
|
-29.07
-0.21%
|
-29.01
|
| Net Income Common Stockholders |
|
-42.76
+10.75%
|
-47.91
-64.84%
|
-29.07
+0.30%
|
-29.15
|
| Diluted EPS |
|
—
|
-0.47
-62.07%
|
-0.29
+35.56%
|
-0.45
|
| Basic EPS |
|
—
|
-0.47
-62.07%
|
-0.29
+35.56%
|
-0.45
|
| Basic Average Shares |
|
—
|
101.97
+2.97%
|
99.03
+53.44%
|
64.54
|
| Diluted Average Shares |
|
—
|
101.97
+2.97%
|
99.03
+53.44%
|
64.54
|
| Diluted NI Availto Com Stockholders |
|
-42.76
+10.75%
|
-47.91
-64.84%
|
-29.07
+0.30%
|
-29.15
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
0.38
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
193.44
+74.43%
|
110.90
+24.05%
|
89.40
-27.32%
|
123.02
|
| Current Assets |
|
191.66
+75.14%
|
109.43
+24.99%
|
87.55
-28.60%
|
122.62
|
| Cash Cash Equivalents And Short Term Investments |
|
188.26
+74.93%
|
107.62
+29.71%
|
82.97
-31.15%
|
120.51
|
| Cash And Cash Equivalents |
|
18.91
-44.53%
|
34.10
+5.25%
|
32.40
+157.34%
|
12.59
|
| Other Short Term Investments |
|
169.35
+130.32%
|
73.53
+45.38%
|
50.57
-53.14%
|
107.92
|
| Receivables |
|
—
|
—
|
—
|
—
|
| Taxes Receivable |
|
—
|
—
|
—
|
—
|
| Prepaid Assets |
|
1.26
+34.50%
|
0.94
-74.07%
|
3.62
+355.47%
|
0.80
|
| Other Current Assets |
|
2.13
+146.02%
|
0.87
-9.21%
|
0.95
-27.15%
|
1.31
|
| Total Non Current Assets |
|
1.78
+21.13%
|
1.47
-20.69%
|
1.86
+365.16%
|
0.40
|
| Net PPE |
|
0.85
-30.43%
|
1.23
-21.17%
|
1.56
+703.61%
|
0.19
|
| Gross PPE |
|
1.21
-16.68%
|
1.46
-13.94%
|
1.69
+304.06%
|
0.42
|
| Accumulated Depreciation |
|
-0.36
-57.46%
|
-0.23
-70.15%
|
-0.13
+40.44%
|
-0.23
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.51
+45.27%
|
0.35
+14.80%
|
0.30
+43.40%
|
0.21
|
| Construction In Progress |
|
0.00
-85.71%
|
0.01
-58.82%
|
0.02
-67.92%
|
0.05
|
| Other Properties |
|
0.68
-36.85%
|
1.07
-20.18%
|
1.34
+5495.83%
|
0.02
|
| Leases |
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
-77.69%
|
0.13
|
| Other Non Current Assets |
|
0.93
+281.89%
|
0.24
-18.18%
|
0.30
+44.88%
|
0.20
|
| Total Liabilities Net Minority Interest |
|
10.20
-9.43%
|
11.26
+64.18%
|
6.86
-55.93%
|
15.56
|
| Current Liabilities |
|
9.75
-7.23%
|
10.51
+80.44%
|
5.82
-56.54%
|
13.40
|
| Payables And Accrued Expenses |
|
6.70
-12.88%
|
7.69
+96.88%
|
3.90
-19.79%
|
4.87
|
| Payables |
|
3.91
+14.56%
|
3.41
+88.72%
|
1.81
-36.68%
|
2.86
|
| Accounts Payable |
|
3.91
+14.56%
|
3.41
+88.72%
|
1.81
-36.68%
|
2.86
|
| Current Accrued Expenses |
|
2.79
-34.81%
|
4.27
+103.91%
|
2.10
+4.23%
|
2.01
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
2.75
+8.20%
|
2.54
+57.25%
|
1.61
+7.03%
|
1.51
|
| Current Debt And Capital Lease Obligation |
|
0.31
+7.72%
|
0.28
-6.86%
|
0.31
-95.64%
|
7.03
|
| Current Debt |
|
—
|
—
|
—
|
7.00
|
| Other Current Borrowings |
|
—
|
—
|
—
|
7.00
|
| Current Capital Lease Obligation |
|
0.31
+7.72%
|
0.28
-6.86%
|
0.31
+1124.00%
|
0.03
|
| Other Current Liabilities |
|
—
|
—
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.45
-40.29%
|
0.75
-27.62%
|
1.03
-52.13%
|
2.16
|
| Long Term Debt And Capital Lease Obligation |
|
0.45
-40.29%
|
0.75
-27.62%
|
1.03
-52.07%
|
2.15
|
| Long Term Debt |
|
—
|
—
|
—
|
2.15
|
| Long Term Capital Lease Obligation |
|
0.45
-40.29%
|
0.75
-27.62%
|
1.03
+51500.00%
|
0.00
|
| Other Non Current Liabilities |
|
—
|
—
|
—
|
0.00
|
| Stockholders Equity |
|
183.24
+83.90%
|
99.64
+20.71%
|
82.55
-23.18%
|
107.46
|
| Common Stock Equity |
|
183.24
+83.90%
|
99.64
+20.71%
|
82.55
-23.18%
|
107.46
|
| Capital Stock |
|
0.13
+36.17%
|
0.09
+38.24%
|
0.07
+13.33%
|
0.06
|
| Common Stock |
|
0.13
+36.17%
|
0.09
+38.24%
|
0.07
+13.33%
|
0.06
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
128.31
+37.08%
|
93.60
+37.08%
|
68.28
+13.91%
|
59.94
|
| Ordinary Shares Number |
|
128.31
+37.08%
|
93.60
+37.08%
|
68.28
+13.91%
|
59.94
|
| Additional Paid In Capital |
|
512.77
+32.66%
|
386.53
+20.18%
|
321.64
+1.28%
|
317.59
|
| Retained Earnings |
|
-329.80
-14.90%
|
-287.05
-20.04%
|
-239.13
-13.84%
|
-210.07
|
| Gains Losses Not Affecting Retained Earnings |
|
0.15
+142.62%
|
0.06
+310.34%
|
-0.03
+76.23%
|
-0.12
|
| Other Equity Adjustments |
|
0.15
+142.62%
|
0.06
+310.34%
|
-0.03
+76.23%
|
-0.12
|
| Total Equity Gross Minority Interest |
|
183.24
+83.90%
|
99.64
+20.71%
|
82.55
-23.18%
|
107.46
|
| Total Capitalization |
|
183.24
+83.90%
|
99.64
+20.71%
|
82.55
-24.69%
|
109.61
|
| Working Capital |
|
181.91
+83.89%
|
98.92
+21.04%
|
81.72
-25.17%
|
109.22
|
| Invested Capital |
|
183.24
+83.90%
|
99.64
+20.71%
|
82.55
-29.21%
|
116.61
|
| Total Debt |
|
0.75
-27.03%
|
1.03
-22.87%
|
1.34
-85.42%
|
9.18
|
| Capital Lease Obligations |
|
0.75
-27.03%
|
1.03
-22.87%
|
1.34
+4855.56%
|
0.03
|
| Net Tangible Assets |
|
183.24
+83.90%
|
99.64
+20.71%
|
82.55
-23.18%
|
107.46
|
| Tangible Book Value |
|
183.24
+83.90%
|
99.64
+20.71%
|
82.55
-23.18%
|
107.46
|
| Derivative Product Liabilities |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-42.09
-10.02%
|
-38.26
-20.64%
|
-31.71
-12.55%
|
-28.18
|
| Cash Flow From Continuing Operating Activities |
|
-42.09
-10.02%
|
-38.26
-20.64%
|
-31.71
-12.55%
|
-28.18
|
| Net Income From Continuing Operations |
|
-42.76
+10.75%
|
-47.91
-64.84%
|
-29.07
+0.30%
|
-29.15
|
| Depreciation Amortization Depletion |
|
0.14
-2.04%
|
0.15
+19.51%
|
0.12
+186.05%
|
0.04
|
| Depreciation |
|
—
|
—
|
—
|
0.04
|
| Depreciation And Amortization |
|
0.14
-2.04%
|
0.15
+19.51%
|
0.12
+186.05%
|
0.04
|
| Other Non Cash Items |
|
0.46
+0.65%
|
0.46
-51.43%
|
0.95
+82.12%
|
0.52
|
| Stock Based Compensation |
|
5.18
+44.51%
|
3.59
+59.68%
|
2.25
-3.44%
|
2.33
|
| Asset Impairment Charge |
|
—
|
0.00
-100.00%
|
0.39
|
0.00
|
| Operating Gains Losses |
|
0.01
|
—
|
0.01
-93.20%
|
0.15
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
0.15
|
| Gain Loss On Sale Of PPE |
|
0.01
|
0.00
-100.00%
|
0.01
|
0.00
|
| Change In Working Capital |
|
-3.49
-151.14%
|
6.83
+277.46%
|
-3.85
-212.51%
|
-1.23
|
| Change In Prepaid Assets |
|
-1.48
-155.58%
|
2.66
+193.30%
|
-2.85
-374.21%
|
-0.60
|
| Change In Payables And Accrued Expense |
|
-2.01
-148.30%
|
4.17
+518.05%
|
-1.00
-58.25%
|
-0.63
|
| Change In Accrued Expense |
|
-1.42
-155.21%
|
2.56
+4828.85%
|
0.05
+108.14%
|
-0.64
|
| Change In Payable |
|
-0.60
-137.26%
|
1.60
+253.00%
|
-1.05
-11755.56%
|
0.01
|
| Change In Account Payable |
|
-0.60
-137.26%
|
1.60
+253.00%
|
-1.05
-11755.56%
|
0.01
|
| Investing Cash Flow |
|
-94.11
-337.14%
|
-21.53
-136.23%
|
59.43
+155.35%
|
-107.37
|
| Cash Flow From Continuing Investing Activities |
|
-94.11
-337.14%
|
-21.53
-136.23%
|
59.43
+155.35%
|
-107.37
|
| Net PPE Purchase And Sale |
|
-0.01
+65.71%
|
-0.04
+74.45%
|
-0.14
+13.84%
|
-0.16
|
| Purchase Of PPE |
|
-0.01
+65.71%
|
-0.04
+74.45%
|
-0.14
+13.84%
|
-0.16
|
| Capital Expenditure |
|
-0.01
+65.71%
|
-0.04
+74.45%
|
-0.14
+13.84%
|
-0.16
|
| Net Investment Purchase And Sale |
|
-94.09
-337.79%
|
-21.49
-136.08%
|
59.56
+155.56%
|
-107.21
|
| Purchase Of Investment |
|
-170.66
-73.33%
|
-98.46
-891.37%
|
-9.93
+92.13%
|
-126.22
|
| Sale Of Investment |
|
76.57
-0.52%
|
76.97
+10.75%
|
69.50
+265.75%
|
19.00
|
| Financing Cash Flow |
|
121.01
+96.82%
|
61.48
+877.29%
|
-7.91
-107.11%
|
111.31
|
| Cash Flow From Continuing Financing Activities |
|
121.01
+96.82%
|
61.48
+877.29%
|
-7.91
-107.11%
|
111.31
|
| Net Issuance Payments Of Debt |
|
-0.01
+91.27%
|
-0.13
+98.67%
|
-9.50
-62.94%
|
-5.83
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Repayment Of Debt |
|
-0.01
+91.27%
|
-0.13
+98.67%
|
-9.50
-62.94%
|
-5.83
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Long Term Debt Payments |
|
-0.01
+91.27%
|
-0.13
+98.67%
|
-9.50
-62.94%
|
-5.83
|
| Net Long Term Debt Issuance |
|
-0.01
+91.27%
|
-0.13
+98.67%
|
-9.50
-62.94%
|
-5.83
|
| Short Term Debt Payments |
|
—
|
0.00
+100.00%
|
-9.41
|
—
|
| Net Short Term Debt Issuance |
|
—
|
0.00
+100.00%
|
-9.41
|
—
|
| Net Common Stock Issuance |
|
108.15
+76.88%
|
61.15
+3475.79%
|
1.71
-98.38%
|
105.41
|
| Proceeds From Stock Option Exercised |
|
12.95
+2691.81%
|
0.46
+226.76%
|
0.14
-98.81%
|
11.98
|
| Net Other Financing Charges |
|
-0.08
|
—
|
-0.26
-4.45%
|
-0.25
|
| Changes In Cash |
|
-15.18
-993.12%
|
1.70
-91.42%
|
19.81
+181.71%
|
-24.24
|
| Beginning Cash Position |
|
34.10
+5.25%
|
32.40
+157.34%
|
12.59
-65.82%
|
36.83
|
| End Cash Position |
|
18.91
-44.53%
|
34.10
+5.25%
|
32.40
+157.34%
|
12.59
|
| Free Cash Flow |
|
-42.10
-9.95%
|
-38.29
-20.23%
|
-31.85
-12.40%
|
-28.33
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
0.00
-98.79%
|
0.33
-44.28%
|
0.59
|
| Amortization Of Securities |
|
-1.64
-19.82%
|
-1.37
+35.67%
|
-2.12
-156.33%
|
-0.83
|
| Common Stock Issuance |
|
108.15
+76.88%
|
61.15
+3475.79%
|
1.71
-98.38%
|
105.41
|
| Issuance Of Capital Stock |
|
108.15
+76.88%
|
61.15
+3475.79%
|
1.71
-98.38%
|
105.41
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-17 View
- 10-K2026-03-17 View
- 8-K2026-03-17 View
- 8-K2026-03-09 View
- 42026-02-20 View
- 42026-02-20 View
- 42026-02-20 View
- 42026-02-20 View
- 42026-02-20 View
- 42026-01-12 View
- 8-K2025-12-05 View
- 42025-12-03 View
- 10-Q2025-11-13 View
- 8-K2025-11-13 View
- 8-K2025-08-20 View
- 10-Q2025-08-07 View
- 8-K2025-08-07 View
- 8-K2025-06-17 View
- 42025-06-13 View
- 42025-06-13 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|